Castle Biosciences DecisionDx-UMSeq Panel
Castle Biosciences has launched the DecisionDx-UMSeq panel, which uses next-generation sequencing to identify somatic mutations in genes relevant to uveal melanoma. The panel will evaluate DNA mutations in seven genes known to be relevant to UM: GNAQ, GNA11, PLCB4, CYSLTR2, SF3B1, exons 1-2 of EIF1AX, and coding exons of BAP1. While no currently available therapies target pathways affected by the gene mutations evaluated in the panel, the genomic information may be useful in the future to inform patient care as UM research and therapeutic options evolve, the company noted. The assay will complement Castle's DecisionDx-UM gene expression profile test for assessing likelihood of metastasis in UM.
Dovetail Genomics Hi-C Kit
Dovetail Genomics has introduced the Dovetail Hi-C Kit with cloud-based HiRise software for genome assembly, its first commercial kit, enabling researchers to generate chromosome-scale assemblies in house. Dovetail also said that it has lowered the pricing of its scaffolding service, a result of efficiencies achieved by building and delivering hundreds of assemblies over the last few years.
Thermo Fisher Scientific Ion Torrent Oncomine Pan-Cancer Cell-Free and Tumor Mutation Load Assays
Thermo Fisher Scientific has launched two new Oncomine assays. The Ion Torrent Oncomine Pan-Cancer Cell-Free Assay is designed for the analysis of tumor DNA and RNA for all major classes of mutations. The assay, which targets more than 50 genes across multiple tumor types, including lung, colorectal, breast, pancreatic, and thyroid cancer, requires a single vial of blood and as little as 1 nanogram of nucleic acid input material and can be completed in two days. The Ion Torrent Oncomine Mutation Load Assay sequences 409 genes using as little as 20 nanograms of DNA from formalin-fixed paraffin-embedded tissue. It is designed to improve selection strategies for immunotherapy clinical trials.
For more new products and services, please visit the New Products page on our website.